{"analyses":[{"ciLowerLimit":"0.44","ciNumSides":"TWO_SIDED","ciPctValue":"99.8","ciUpperLimit":"0.89","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.63","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The median for Overall Survival and Upper Limit have not been reached. There were an insufficient number of participants with events.","groupId":"OG000","lowerLimit":"28.16","upperLimit":"NA","value":"NA"},{"comment":"The median for Overall Survival and Upper Limit have not been reached. There were an insufficient number of participants with events.","groupId":"OG001","lowerLimit":"22.08","upperLimit":"NA","value":"25.95"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"425"},{"groupId":"OG001","value":"422"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to the date of death from any cause. Survival time was censored at the date of last contact (\"last known alive date\") for subjects who were alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg combined with Ipilimumab 1 mg/kg solutions intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solutions intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends","id":"OG000","title":"Nivolumab + Ipilimumab"},{"description":"Sunitinib 50 mg capsules by mouth once daily for 4 weeks then 2 weeks off, continuously until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends After completion of final analysis eligible participants may switch from receiving Sunitinib to receiving Nivolumab 3 mg/kg IV combined with Ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then Nivolumab 240mg flat dose IV every 2 weeks","id":"OG001","title":"Sunitinib"}],"paramType":"MEDIAN","populationDescription":"All Intermediate/Poor-Risk Participants","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of death (assessed up to June 2017, approximately 31 months)","title":"Overall Survival (OS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)","type":"PRIMARY","unitOfMeasure":"months"}